Breaking Finance News

A statement released earlier today by Raymond James about Voyager Therapeutics (NASDAQ:VYGR) bumps the target price to $35.00

Boasting a price of $24.00, Voyager Therapeutics (NASDAQ:VYGR) traded 5.25% higher on the day. With the last stock price close up 122.51% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Voyager Therapeutics has recorded a 50-day average of $15.89 and a two hundred day average of $11.35. Volume of trade was up over the average, with 426,548 shares of VYGR changing hands over the typical 275,054

Raymond James bumped up the target of Voyager Therapeutics (NASDAQ:VYGR) to $35.00 stating a potential upside of 0.46%.

On 8/17/2017, Evercore ISI released a statement for Voyager Therapeutics (NASDAQ:VYGR) bumped up the target price from $0.00 to $12.00 that suggested an upside of 0.39%.

Performance Chart

Voyager Therapeutics (NASDAQ:VYGR)

With a total market value of $0, Voyager Therapeutics has with a one year low of $8.10 and a one year high of $25.75 .

A total of 3 equity analysts have released a ratings update on VYGR. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $28.00.

Brief Synopsis About Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.